Brigham and Women's Hospital
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective cardiac surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
This is a phase 2a, randomized, double-blind, parallel-group, placebo-controlled clinical trial in adult patients undergoing elective cardiac surgery. A total of 90 patients will be randomized 1:1:1 to placebo or to one of two dosing regimens of NMN seven days prior to surgery as follows: Arm A: NMN 1,000 mg PO twice daily, administered for 7 days preoperatively, on the day of surgery, and for 3 days postoperatively Arm B: NMN 1,000 mg PO twice daily, administered for 2 days preoperatively, on the day of surgery, and for 3 days postoperatively Arm C: Placebo PO twice daily, administered for…
Inclusion Criteria: 1. Age ≥18 years 2. Scheduled to undergo elective isolated CABG surgery and/or valve surgery with cardiopulmonary bypass (CPB) 3. At increased risk of postoperative complications based on ≥1 of the following: 1. Age ≥65 years 2. eGFR \<45 ml/min/1.73m2 3. Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery 4. Diabetes mellitus 5. Proteinuria defined as urine albumin-to-creatinine ratio \>30 mg/g creatinine, urine protein-to-creatinine ratio \>0.05g/g creatinine, or 2+ or greater pro…
An orally-administered stable crystalline tablet formulation of NMN
matching placebo tablets
Arctuva estimate
Verify or correct the compensation shown for this listing.